XT
KROS icon

XTX Topco’s Keros Therapeutics KROS Stock Holding History

XTX Topco’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$637K Sell
59,531
-28,791
-33% -$321K 0.01% 2228
2026
Q1 		$975K Buy
88,322
+77,898
+747% +$1.2M 0.02% 1439
2025
Q4 		$212K Buy
+10,424
New +$183K 0.01% 2358
2025
Q3 		– Sell
-54,145
Closed -$723K – 2926
2025
Q2 		$723K Buy
54,145
+6,024
+13% +$81.3K 0.03% 859
2025
Q1 		$490K Buy
+48,121
New +$559K 0.03% 1048
2024
Q3 		– Sell
-4,996
Closed -$228K – 2353
2024
Q2 		$228K Buy
+4,996
New +$268K 0.02% 1147

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

XTX Topco's KROS Position: Q2 2026 in Review

XTX Topco reduced its Keros Therapeutics (KROS) stake by 33% in Q2 2026, selling an estimated $321K and leaving 59,531 shares worth $637K. The position accounts for 0.01% of the portfolio, ranked #2228.

XTX Topco first reported a position in KROS in Q2 2024 and has held it in 6 quarters since. The position peaked at $975K in Q1 2026. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • XTX Topco held 59,531 shares of Keros Therapeutics worth $637K as of Q2 2026.
  • XTX Topco sold 28,791 Keros Therapeutics shares in Q2 2026, an estimated $321K.
  • Keros Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2228 holding.
  • XTX Topco first reported a position in Keros Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • XTX Topco's Keros Therapeutics position peaked at $975K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.